Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rang in Aktien #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Aktienkurs
$16.85
Zuletzt synchronisiert: 2023-07-07
Marktkapitalisierung
$393.50M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CH
Handel VectivBio Holding AG (VECT)

Kategorie

Dividendenrendite-Verlauf für VectivBio Holding AG (VECT)
Dividendenrendite (TTM) von VectivBio Holding AG (Aktienkürzel: VECT) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für VectivBio Holding AG (VECT) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
2.48%
AU
0.00%
US
0.00%
CH